- Recommendation ID
- Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the context of research. Research studies should address whether epiretinal brachytherapy reduces the progression of wet AMD and whether it can reduce the number of injections of antivascular endothelial growth factor agents (anti-VEGF) required. Long-term outcomes should be reported.
- Any explanatory notes
- Current evidence on the efficacy of epiretinal brachytherapy for wet agerelated macular degeneration (AMD) is inadequate and limited to small numbers of patients. With regard to safety, vitrectomy has well-recognised complications and there is a possibility of subsequent radiation retinopathy.
Source guidance details
- Comes from guidance
- Epiretinal brachytherapy for wet age-related macular degeneration
- Date issued
- December 2011
|Is this a recommendation for the use of a technology only in the context of research?||Yes|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|